Researchers recently discovered that an experimental cancer vaccine offers "a promising approach" to preventing cancers from ...

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs ...

Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

In a phase 1 study, ELI-002 2P improved relapse-free survival in pancreatic and colorectal cancer, with stronger benefit in ...

Anocca AB ( Anocca ), a clinical-stage T-cell immunotherapy company, raised SEK ~440 million (USD ~46 million) in financing. Mellby Gård led the financing with strong support from AMF, Ramsbury, and ...

For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease ...

The season is very close to starting for Real Madrid, who will host Osasuna this coming Tuesday at the Santiago Bernabéu ...

Phase 1 trial of a pancreatic cancer vaccine targeting mutant KRAS shows strong immune responses, extended survival, and ...

A new study reveals promising results for a vaccine targeting colorectal and pancreatic cancers. Researchers from the ...